Canton Biologics/汉腾生物

Merry Christmas from Canton Biologics! As we celebrate this joyous season, we are grateful for the incredible partnerships and collaborations we've had this year. At Canton Biologics, we remain inspired by the potential of biotechnology to improve lives and shape a healthier future. Wishing you all a Merry Christmas filled with peace, happiness, and prosperity. Here’s to continued growth and success in the year ahead! #MerryChristmas #Gratitude #Biotechnology #EmpowerTheFuture

Merry Christmas Eve from Canton Biologics! As we gather to celebrate this festive season, we want to express our gratitude for the partnerships and collaborations that have made this year meaningful. At Canton Biologics, we remain committed to innovation in biotechnology, always with the goal of empowering a healthier tomorrow. Wishing you all peace, joy, and warmth this holiday season! #ChristmasEve #Gratitude #EmpowerTheFuture

Happy International Universal Health Coverage Day! At Canton Biologics, we are proud to contribute to global health by advancing innovative biotechnology solutions. As we celebrate this important day, we reaffirm our commitment to improving access to quality healthcare for all. Together, we can build a healthier, more equitable future for everyone. #HealthCoverageForAll #UniversalHealthCoverage #EmpowerTheFuture

🏸 Canton Biologics recently held a fun and energetic badminton tournament! It was a great way to showcase our team's vitality and strong sense of togetherness. 💪 Let's keep this spirit alive—on and off the court! #TeamCanton #WorkHardPlayHard #TeamEnergy

Case Study: Enhanced Protein Expression with Canton Biologics' Canvector® 📌 Background Canton Biologics developed Canvector®, a recombinant protein vector system designed to boost expression efficiency through parallel testing of multiple vector strengths. ⛏️ Challenges Data indicates that the well-regarded Company A has achieved protein expression levels around 0.8-1.0 g/L, highlighting the common challenge of reaching higher yields without compromising quality. 🔬 Actions Using Canvector®, we performed parallel tests to identify the optimal vector for each protein, significantly boosting expression levels. 🧬 Results · Higher Yield: Expression levels improved by 2-3x, reaching over 2g/L, with some RSV molecules achieving up to 3g/L. · Efficiency: Our vector system providing a scalable solution for higher protein yields. Contact us: BD@cantonbio.com #Canvector #ProteinExpression #Biotechnology #Innovation #EmpowerTheFuture

Happy Thanksgiving from Canton Biologics! As we reflect on this past year, we want to express our heartfelt gratitude to everyone we’ve met and worked with. Your support, collaboration, and partnership have been essential to our growth and success at Canton Biologics. We are excited about the future and look forward to continuing our journey together—pushing the boundaries of biotechnology and making meaningful contributions to global health. Wishing you all a wonderful Thanksgiving filled with joy, warmth, and gratitude! #Thanksgiving #Gratitude #Collaboration #EmpowerTheFuture

Case Study: Breakthrough in Bivalent Vaccine Production at Canton Biologics 📃 Background Canton Biologics aimed to exceed industry standards in bivalent vaccine production by increasing yield and ensuring exceptional purity. 🚨 Challenges The key challenge was significantly reducing host cell proteins (HCP) without compromising product purity. While the industry-leading Company A had HCP residuals of 900 ppm, our goal was to achieve much lower levels with stable, high yield. 🔬 Actions We employed advanced DSP techniques to enhance HCP removal while maintaining purity using SEC analysis. 💡 Results · Purity: SEC purity exceeded 99%. · HCP Reduction: HCP residuals were reduced to <10ppm, significantly lower than industry-leading Company A. · RSV Expression: RSV molecule A expressed at 2g/L, and RSV molecule B at 3.2g/L. Contact us: BD@cantonbio.com #Biotechnology #Innovation #HCPRemoval #EmpowerTheFuture

🔬 World Science Day for Peace and Development! At Canton Biologics, we are proud to celebrate the power of science in driving positive change across the world. As a company committed to reliable, efficient, and innovative research, we believe that biotechnology holds the key to solving many of today's global challenges. 🌏 Our mission—Empower Future with Biotechnology—drives us to constantly push boundaries and explore new frontiers, all with the goal of making the world a better place through scientific advancement. Let's continue working together to harness the potential of science for peace, sustainability, and development! 🥂 #WorldScienceDay #Biotechnology #Innovation #EmpowerTheFuture #CantonBiologics

Respiratory Syncytial Virus (RSV) is a highly prevalent and contagious respiratory infection, and a leading cause of bronchiolitis and pneumonia. Each year, RSV affects more than 64 million people worldwide. 😵💫 📃 A recent review published in The Lancet Infectious Diseases (IF=36.4), titled "Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape," highlights the clinical development of RSV vaccines and monoclonal antibodies, focusing on different target populations, antigens, and trial outcomes. Canton Biologics has supported numerous biopharmaceutical companies globally by providing development and manufacturing services for biologics, including recombinant proteins. We welcome new collaborations to advance the development of biopharmaceutical innovations. 🥂 Read the paper: https://lnkd.in/gg4kymTj #RSV #Biopharma #Biotechnology #MonoclonalAntibodies #VaccineDevelopment #Biopharmaceuticals #Biologics #InnovationInHealthcare #GlobalHealth

Canton Biologics’ bispecific antibody platform is equipped with rich experience in developing a wide range of symmetric and asymmetric configurations. Our team is capable of completing the development process from DNA to IND within 12 months. With exceptional performance in high expression, yield, and purity, we consistently achieve an average clone expression level of nearly 10g/L with a purity of 99%. 📃 Case Study: EMA-Approved Drug Production Transition to China 🚨 Challenges: Due to the change in production site, the manufacturing process parameters had to be adjusted to fit the new facility’s equipment. 🛡️ Solutions: Canton Biologics ensured high-quality drug production by implementing rigorous process transfer and validation, analytical method transfer and validation, comparability studies, multiple GMP batch productions, quality research, and stability studies. 🧬 Results: Through a series of process optimizations, Canton Biologics achieved an IgG content of nearly 200mg/L, exceeding the process control requirement of 130mg/L and surpassing the original production site’s expression level. #BiotechInnovation #Biopharma #DrugDevelopment #AntibodyTherapy #GMP #PharmaceuticalExcellence #ProcessOptimization #Biotechnology #Healthcare